Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02695433 · ClinicalTrials.gov registry record · NA

Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers

A NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

Completed
Registry status
NA
Development phase
124
Enrollment target

NCT02695433: Completed NA study, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

NCT02695433 is a NA study that has completed, run by Clinical Nutrition Research Center, Illinois Institute of Technology. The registered enrollment target is 124 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02695433, a NA study, has completed, sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology.

COMPLETED
Registry status
NA
Development phase
124 participants
Enrollment target

Study Summary

The primary goal is to to characterize the effects of consuming 1 avocado fruit 7 days / week (5-7 days is acceptable) compared to a no avocado relatively low fat, carbohydrate control treatment over a 12 week period on insulin sensitivity as measured by the Matsuda composite index of insulin sensitivity (MISI).

Primary Outcome

insulin sensitivity as measured by the Matsuda composite index

Interventions

  • DIETARY_SUPPLEMENT Active
  • DIETARY_SUPPLEMENT Control

Trial Details

FieldValue
Enrollment Target 124 participants
Start Date 2016-03-01
Est. Completion 2021-05-15
Phase NA

What the finished NCT02695433 record still lists

NCT02695433 is an interventional study that assigns participants to a tested intervention. The registered 124 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).

The record links to 0 conditions, and to 2 interventions - of which Active is the first listed.

NCT02695433 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02695433 about?

NCT02695433 is a clinical study titled "Replacing Refined Carbohydrates With Healthy Fats on Cardio-metabolic Markers". The primary goal is to to characterize the effects of consuming 1 avocado fruit 7 days / week (5-7 days is acceptable) compared to a no avocado relatively low fat, carbohydrate control treatment over a 12 week period on insulin sensitivity as measured by the Matsuda composite index of insulin sensit...

What is the current status of trial NCT02695433?

This trial is currently completed. It is a NA study. The enrollment target is 124 participants. The study started on 2016-03-01. Estimated completion is 2021-05-15.

What interventions are being tested in trial NCT02695433?

The interventions under investigation include: Active (DIETARY_SUPPLEMENT), Control (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT02695433?

This trial is sponsored by Clinical Nutrition Research Center, Illinois Institute of Technology, which has 59 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02695433's enrollment target sits among peer trials

124 758th of 2000 higher than 1,239 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02523014 · 124 participants · Phase 2

    Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

  • NCT02670707 · 124 participants · Phase 3

    Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)

  • NCT02830724 · 124 participants · Phase 1

    Administering Peripheral Blood Lymphocytes Transduced With a CD70-Binding Chimeric Antigen Receptor to People With CD70 Expressing Cancers

  • NCT04748809 · 124 participants · NA

    Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02695433, the US trial registry maintained by the National Library of Medicine. NCT02695433 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.